Virtual Keystone Symposia
The Genome Editing Revolution
Translating Genome Editing Technologies into Human Therapies
FREE LIVE Webcast | Thursday, November 10, 2016 | 3:15—4:45 PM EST
Sponsored by Editas Medicine, Inc.
Depending on your browser settings, you may need to enable cookies or open this window in a new page.
Viewing the webcast on Chrome or Firefox is preferred.
The Genome Editing Revolution: Translating Genome Editing Technologies into Human Therapies
Join us for the Virtual Keystone Symposia global webcast on genome editing. For more information and to register, please visit http://www.keystonesymposia.org/vks
Live Webcast from WGBH in Boston, MA
Email Share Tweet #VKSGenome
Join us for the Virtual Keystone Symposia global webcast on genome editing. Recent advances in genome editing nucleases have led to their broader application in biomedical research and dramatically accelerated efforts to develop therapeutics based on this technology. In this dynamic, interactive panel event, experts in genome editing and gene therapy from academia and industry will discuss the following topics and others relevant to clinical translation of the technology:
J. Keith Joung is a leading innovator in the field of genome editing. He is currently Pathologist, an MGH Research Scholar, and Associate Chief of Pathology for Research at Massachusetts General Hospital (MGH) as well as Professor of Pathology at Harvard Medical School. He is also a member of the Center for Cancer Research and the Center for Computational and Integrative Biology at MGH. Dr. Joung has been a pioneer in the development of engineered zinc finger, transcription activator-like effector (TALE), and CRISPR-Cas technologies and their applications for targeted genome editing and epigenome editing of human cells. He has received numerous awards including an NIH Director's Pioneer Award, an NIH Director's Transformative Research Project R01 Award, the Jim and Ann Orr MGH Research Scholar Award, and election into the American Association of University Pathologists. He is a Scientific Advisory Board member of Horizon Discovery and Transposagen Biopharmaceuticals. He is also a scientific co-founder of Editas Medicine, a company dedicated to the translation of genome editing technologies for therapy of human diseases.
Dr. Joung holds a PhD in genetics from Harvard University, an MD from Harvard Medical School, and an AB in biochemical sciences
from Harvard College.
Back to top
Alexandra Glucksmann is Chief Operating Officer and founding employee at Editas Medicine Inc., a gene editing company whose mission
is to translate its genome editing technology into a novel class of human therapeutics. Previously, Dr. Glucksmann was Senior Vice President
of Research and Development at Cerulean Pharma, which she joined at its founding. Cerulean Pharma is a clinical-stage company developing
innovative nanopharmaceutical tumor-targeting products. Prior to joining Cerulean in 2006, she spent 13 years at Millennium Pharmaceuticals
which she joined in 1993 as one of its first scientists. At Millennium, she held a series of science positions with increasing responsibility,
ultimately becoming Vice President of all platform technology groups before moving into a senior role in strategic program management
and operations. She serves on the board of Women in the Enterprise of Science and Technology (WEST). Dr. Glucksmann was a post-doctoral
fellow at the Massachusetts Institute of Technology and holds a PhD with honors from The University of Chicago.
Back to top
Michael Holmes has served as Vice President, Research since July 2015 and currently oversees Sangamo's research activities.
He joined Sangamo in May 2001 as a Scientist and became a Team Leader in 2002, focusing on the development of novel cell-based approaches
to screen compound libraries. He was promoted to Director, Therapeutic Gene Modification in 2004, and Senior Director in 2009, where he
pioneered the use of ZFNs for genome editing in transformed and primary human cells, including hematopoietic stem cells. Dr. Holmes has
authored over 55 publications in the field of genome editing and gene regulation, as well as numerous patents. Prior to joining Sangamo,
he worked as a post-doctoral fellow in Dr. Gerald Rubin's lab at the University of California, Berkeley. Dr. Holmes received a BS in
Molecular Biology from the University of California, San Diego, and his PhD in Molecular and Cell Biology from the University of
Back to top
Rachel Haurwitz is a co-founder of Caribou Biosciences and has been President and CEO since its inception. She has a research background in
CRISPR-Cas biology, and in 2014, was named by Forbes magazine to the "30 Under 30" list in Science and Healthcare. She is also a
co-founder of Intellia Therapeutics where she is a member of the board of directors. Dr. Haurwitz is an inventor on several patents and
patent applications covering multiple CRISPR-derived technologies, and she has co-authored scientific papers in high-impact journals
characterizing CRISPR-Cas systems. She earned an AB in Biological Sciences from Harvard College and a PhD in Molecular
and Cell Biology from the University of California, Berkeley.
Back to top
James M. Wilson, MD, PhD is a Professor in the Perelman School of Medicine at the University of Pennsylvania where he has been at the nexus of the field of gene therapy from its birth. Dr. Wilson began his work in gene therapy during his graduate studies at the University of Michigan over 30 years ago. He created the first and largest academic-based program in gene therapy after being recruited to Penn in 1993, initially focusing on the clinical translation of existing gene transfer technologies but soon redirecting his efforts to the development of second and third generation gene transfer platforms, the first of which was licensed to a biotechnology company he founded that resulted in the first, and only, commercially approved gene therapy in the western hemisphere.
More recently, his laboratory discovered a family of viruses from primates that could be engineered to be very effective gene transfer vehicles. Dr. Wilson has also been active in facilitating the commercial development of these new gene therapy platforms through the establishment of several biotechnology companies. He is currently leading a national dialogue on the challenges of commercializing these potentially lifesaving treatments due to the disruptive nature they will have on traditional business models. Throughout his career, the focus of Dr. Wilson's research has been rare inherited diseases, ranging from cystic fibrosis to dyslipidemias to a variety of metabolic disorders. He is the founder of a 501(c)3 called Health Through Fitness in Orphan Diseases and Director of a bicycle team called Rare Disease Cycling whose participants compete at a national level and help raise money for rare disease research.
Dr. Wilson has published over 550 papers, reviews, commentaries and editorials in peer-reviewed literature and is an inventor
on over 117 patents. He was the second President of the American Society of Gene Therapy, the 2014 recipient of the William
Osler Patient Oriented Research Award of the University of Pennsylvania and 2015 recipient of the Scientific Achievement Award from Pennsylvania
Bio. He was cited by the journal Nature Biotechnology as the "second most productive bio-entrepreneur in life sciences."
Back to top